Praxis Precision Medicines, Inc. (PRAX)
Data as of Nov 3, 11:20 AM ETPrices may be delayedHow our data works
Res / Sup are automatic swing levels for educational reference only — not signals or advice.
Prices may be delayed. For informational purposes only — not investment advice.
PRAX key stats
PRAX GlowScore: Active
A 0–100 read on today's activity from volume, momentum and intraday range. Not a buy or sell signal.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
What's moving PRAX today
Updated November 3, 2026As of November 3, 2026, Praxis Precision Medicines, Inc. (PRAX) stock climbed to $284.05, up 3.67% (+$10.06) versus the previous close. On the day, shares have traded between $276.00 and $286.04. That puts PRAX around the middle of its 52-week range of $154.45 to $392.70. Praxis Precision Medicines, Inc. operates in the pharmaceutical preparations space and carries a market capitalization of roughly $7.98 billion, with about 46.5K shares changing hands.
Latest PRAX news
- Is Investor Day Plans Altering The Investment Case For Praxis Precision Medicines (PRAX)?Yahoo Finance· Oct 28, 9:10 AM ET
- Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference ParticipationYahoo Finance· Oct 27, 4:01 PM ETCNS
- Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsightYahoo Finance· Oct 27, 10:31 AM ET
- Is Praxis Precision Medicines (PRAX) Priced Too Highly On Book Value?Yahoo Finance· Oct 18, 5:12 PM ET
- Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst callsYahoo Finance· Oct 16, 9:38 AM ET
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance· Oct 2, 4:01 PM ETCNS
- Praxis (PRAX) Q2 2026 Earnings Call Transcriptfool.com· Aug 13, 12:29 PM ET
- 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This YearYahoo Finance· Aug 11, 10:01 AM ET
Source: Yahoo Finance RSS · Updated November 3, 2026
Want PRAX headlines, alerts and AI research in one place? Create a free account →
PRAX buzz on Stocktwits
1,831 watchers$PRAX PART #1 FYI - Here’s a short summary of the targeted anti-epileptic/anti-seizure therapeutics mentioned below by Merlin Trader. If you have technical questions or want additional information, please look up the specific study at www.clinicaltrials.gov. For analyst share …
@Trainguy1· Nov 3, 9:11 AM ET
$PRAX PART #2 • Praxis Relutrigine: Currently this drug is under FDA review for possible marketing approval to treat SCN2A/SCN8A developmental and epileptic encephalopathies (DEEs). The drug is also currently undergoing a phase 3 clinical trial for treating a broad set of DEEs…
@Trainguy1· Nov 3, 9:10 AM ET
$PRAX PART #3 • Rapport RAP-219: Currently this oral drug is undergoing phase 3 clinical trials for treating adults with focal seizures (FOCUS 1 & FOCUS 2 studies). If the quantity of seizures per month decreases, then RAP-219 could be approved. • Stoke Zorevunersen: This …
@Trainguy1· Nov 3, 9:09 AM ET
$PRAX $RAPP $STOK $XENE Epilepsy beyond seizure counts: new sector report Praxis (relutrigine in SCN2A/SCN8A DEEs), Rapport (RAP-219 in focal seizures), Stoke (zorevunersen in Dravet syndrome) and Xenon (azetukalner application). The report separates seizure reduction from dis…
@Merlintrader· Nov 1, 4:06 AM ET
$PRAX closed the week at $285.93 (+13.0% w/w, -0.9% Friday), below the 50-day SMA ($301.29) and below the 200-day ($314.83). RSI14 55.0. Support $236.79, resistance $299.12 (20-day range, top). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/prax/
@Merlintrader· Oct 31, 5:39 PM ET
Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →
PRAX Congress & insider trades
Congress amounts are the disclosed ranges; filings can lag the trade date by up to 45 days.
AI research on PRAX
Get an instant AI breakdown of the bull & bear case, key risks, and what analysts are watching.
Not financial advice. This page is for educational purposes only. Data comes from third-party sources, may be delayed or incomplete, and should not be the basis of any investment decision.